These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 15471508)

  • 61. Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs.
    Watson DJ; Harper SE; Zhao PL; Bolognese JA; Simon TJ
    MedGenMed; 2001 Nov; 3(4):6. PubMed ID: 11965201
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Epidemiology and pharmacoeconomic implications of non-steroidal anti-inflammatory drug-associated gastrointestinal toxicity.
    MacDonald TM
    Rheumatology (Oxford); 2000 Dec; 39 Suppl 2():13-20; discussion 57-9. PubMed ID: 11276797
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Preventing the gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs: from risk factor identification to risk factor intervention.
    Bardou M; Barkun AN
    Joint Bone Spine; 2010 Jan; 77(1):6-12. PubMed ID: 20022539
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis.
    Latimer N; Lord J; Grant RL; O'Mahony R; Dickson J; Conaghan PG;
    BMJ; 2009 Jul; 339():b2538. PubMed ID: 19602530
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review.
    Hooper L; Brown TJ; Elliott R; Payne K; Roberts C; Symmons D
    BMJ; 2004 Oct; 329(7472):948. PubMed ID: 15475342
    [TBL] [Abstract][Full Text] [Related]  

  • 67. The hidden cost of nonselective nonsteroidal antiinflammatory drugs in older patients.
    Solomon DH; Glynn RJ; Bohn R; Levin R; Avorn J
    J Rheumatol; 2003 Apr; 30(4):792-8. PubMed ID: 12672201
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Gastrointestinal-related healthcare resource usage associated with a fixed combination of diclofenac and misoprostol versus other NSAIDs.
    Rahme E; Joseph L; Kong SX; Watson DJ; Pellissier JM; LeLorier J
    Pharmacoeconomics; 2001; 19(5 Pt 2):577-88. PubMed ID: 11465302
    [TBL] [Abstract][Full Text] [Related]  

  • 69. An evidence-based evaluation of the gastrointestinal safety of coxibs.
    Bombardier C
    Am J Cardiol; 2002 Mar; 89(6A):3D-9D. PubMed ID: 11909555
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pharmacoeconomic modeling of prior-authorization intervention for COX-2 specific inhibitors in a 3-tier copay plan.
    Stacy J; Shaw E; Arledge MD; Howell-Smith D
    J Manag Care Pharm; 2003; 9(4):327-34. PubMed ID: 14613451
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis.
    Watson DJ; Yu Q; Bolognese JA; Reicin AS; Simon TJ
    Curr Med Res Opin; 2004 Oct; 20(10):1539-48. PubMed ID: 15462687
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Analysis of the costs of NSAID-associated gastropathy. Experience in a US health maintenance organisation.
    Johnson RE; Hornbrook MC; Hooker RS; Woodson GT; Shneidman R
    Pharmacoeconomics; 1997 Jul; 12(1):76-88. PubMed ID: 10169389
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis.
    Bae SC; Corzillius M; Kuntz KM; Liang MH
    Rheumatology (Oxford); 2003 Jan; 42(1):46-53. PubMed ID: 12509612
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Underutilization of preventive strategies in patients receiving NSAIDs.
    Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prevention of NSAID gastropathy in elderly patients. An observational study in general practice and nursing homes.
    van Leen MW; van der Eijk I; Schols JM
    Age Ageing; 2007 Jul; 36(4):414-8. PubMed ID: 17537740
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage.
    Sostres C; Gargallo CJ; Lanas A
    Arthritis Res Ther; 2013; 15 Suppl 3(Suppl 3):S3. PubMed ID: 24267289
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials.
    Schoenfeld P
    Am J Med; 1999 Dec; 107(6A):48S-54S. PubMed ID: 10628593
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis.
    Yun HR; Bae SC
    Rheumatol Int; 2005 Jan; 25(1):9-14. PubMed ID: 13680139
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Non-steroidal anti-inflammatory drugs for acute gout.
    van Durme CM; Wechalekar MD; Buchbinder R; Schlesinger N; van der Heijde D; Landewé RB
    Cochrane Database Syst Rev; 2014 Sep; (9):CD010120. PubMed ID: 25225849
    [TBL] [Abstract][Full Text] [Related]  

  • 80. NSAID induced gastrointestinal damage and designing GI-sparing NSAIDs.
    García-Rayado G; Navarro M; Lanas A
    Expert Rev Clin Pharmacol; 2018 Oct; 11(10):1031-1043. PubMed ID: 30139288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.